



Top 26-30

09 June 2011 | News



Advanced Enzyme Technologies

CEO
 Dr CL Rathi

Business: Manufacturing, R&D and marketing of enzymes

Start-up Year: 1989

26

Address: Sun Magnetica, "A" wing, 5th Floor, LIC Service Road, Louiswadi, Thane (W)- 400 604

Tel: +91-22-41703200

Fax: +91-22-25835159

Website: www.enzyme.com

Advanced Enzyme Technologies (AETL) clocked total sales revenue of ₹154 crore for FY 2010-11 as compared to ₹127 crore in 2009-10. The revenue is expected to increase 30 to 35 percent on a year-on-year basis for the next five to eight years. The company operates primarily in four segments, including human health & nutrition, animal nutrition, food processing, and industrial processing. The company is expected to start its European and Chinese subsidiaries soon. More than 50 percent of the company's sales come from its exports to 53 countries. AETL, which had a overhaul in 2009, developed more than 400 unique enzyme products like luicine amino peptidase (exo-peptidase), candida antarctica lipase b immobilized, a full range of hemicellulase and pectinase enzymes and a full range of grain ethenol enzymes. AETL is also the largest manufacturer of serratiopeptidase, having perfected the art of manufacturing the enzyme over the past 15 years.

Revenue:  154 crore



Lambda Therapeutic Research

MD
Ms Bindi Chudgar

27

Business: Clinical trials implementation, laboratory and data management

Start-up Year: 1999


Address: Near Gujarat High Court, S. G. Highway, Gota, Ahmedabad-380061

Tel: +91-79-40202020

Fax: +91-79-40202021

Website: www.lambda-cro.com

Revenue:  128 crore

Lambda Therapeutic Research recorded an estimated sales revenue of  128 crore for 2010-11. The company offers services such as clinical trials implementation, laboratory and data management, information technology support, medical affairs assistance, quality assurance and bio analysis. The CRO has more than 640 clinical beds globally, including a 16-bed phase I unit in Ahmedabad, a 12-bed phase I unit in Toronto, Canada, a six-bed phase I unit in Warsaw, Poland. The company also has more than 40 LC-MS/MS systems, a CAP/NGSP accredited clinical laboratory, molecular and microbiological laboratory and a low temperature (2-8 °C, -20 °C and -80 °C) controlled storage facility, to store over 4.0 million samples. Lambda Therapeutic Research has additional facilities in Mumbai, India and Erwitte, Germany and has acquired a pharmacovigilance CRO in UK, named Pharm V Solutions.



Concord Biotech

MD and CEO
Mr Sudhir Vaid

28

Business: Manufacturing of bulk drugs

Start-up Year: 2002



Address: 302, Sakar-III, Opp: Gujarat High Court, Off ITO Circle, Ashram Road, Ahmedabad-380014

Tel: +91-79-27544998, 27543557

Fax: +91-79-27540802

Website: www.concordbiotech.com

Revenue:  126.17 crore

Concord Biotech, a R&D-based company that focuses on fermentation and semi-synthetic based products, achieved a total income of  126.17 crore in FY 2010-11 as compared to  110.07 crore in the previous year. It is the largest producer of penicillin-G amidase enzyme, with a market share of 90 percent. It exports this enzyme to a number of companies in China, Europe and the US. Concord also produces and exports lovastatin and tacrolimus and is also starting the production of simvastatin and pravastatin in its new US-FDA approved facility. It now boasts of having one of the largest numbers of bioreactors in India and has setup a lyophilization facility for sterile bulk biopharmaceutical. It also has a manufacturing facility, spread across 28 acres of land, located at Ahmedabad, Gujarat. In FY2010-11, Concord initiated its CRAM business by setting up of its new R&D facility. The company received award for its outstanding contribution to the healthcare sector at Bangalore India Bio 2011.





Ecron Acunova

Founder & Chairman
Mr DA Prasanna

29

Business: Clinical research services

Start-up Year: 1986

Ecron Acunova is a Bangalore-based CRO with offices across India and operations in 14 European countries. The company recorded revenue worth  125 crore in the FY 2010-11 as compared to  97 crore in FY 2009-10. In January 2011, Ecron Acunova expanded its clinical research center for drug development by 80 beds. The company also announced a joint venture with Jamjuree Innovations(JJI), Thailand and will conduct clinical research in key South East Asian countries under the name, Ecron Acunova Company Limited (EACL). In April 2011, Ecron Acunova acquired a majority stake in aCRONordic, a Danish CRO specializing in clinical research in Sweden, Finland and Norway. Since its inception five years ago Ecron has conducted over 250 phase I one studies and

Address: Manipal Acunova Limited, Mobius Towers, SJR i-Park, EPIP, Whitefield, Bangalore-560066

Tel: +91-80-66915700
Fax: +91-80-66915719
Website: www.ecronacunova.com

Revenue: ~~125 crore~~ Image not found or type unknown



Themis Medicare

MD and CEO
 Dr Dinesh Patel

30

Business: Formulations and API of synthetic origin

Start-up Year: 1969

Address: 11/12, Udyog Nagar, S.V.Road, Goregaon (West), Mumbai-400 104

Tel: +91-22-67607080, 28757836
Fax: +91-22-28746621
Website: www.themismedicare.com

Revenue: ~~124 crore~~ Image not found or type unknown

Themis Medicare (TML) achieved a total turnover of ~~124 crore~~ as against ~~90 crore~~ for the year ending March 31, 2010. Image not found or type unknown

TML has a plant located in Hyderabad where lovastatin, simvastatin and other fermentation-based actives are produced.

TML boasts of four state-of-the-art manufacturing facilities at three locations, in Vapi (Gujarat), Hyderabad (Andhra Pradesh) and Haridwar (Uttaranchal). The company has a joint venture partnership with Gedeon Richter (Budapest, Hungary), named Richter-Themis Medicare (India) Private Limited and also has signed a long-term business agreement with Schering-Plough Animal Health Corporation, US (SPAH). Although its first breakthrough product was vitamin B12, TML moved on to manufacture several synthetic API and numerous therapeutics.